drugset
Drugs / Lyso-thermosensitive Liposomal Doxorubicin
last change Dec 2024 re-read 3 minutes ago

Lyso-thermosensitive Liposomal Doxorubicin

Developed for
bone neoplasm · carcinoma · Ewing sarcoma · germ cell tumor · liver and intrahepatic bile duct neoplasm · rhabdomyosarcoma · Wilms tumor
Investigated by
Children's National Research Institute

Trials 1

today NCT04791228 · Ph 2
2023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT04791228 Nov 2022 → Dec 2024 Ewing sarcoma, Wilms tumor, bone neoplasm, carcinoma +3 Children's National Research Institute Withdrawn No outcome recorded Stop: Enrollment

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Lyso-thermosensitive Liposomal Doxorubicin ClinicalTrials.gov intervention name — accepted as the source's own label NCT04791228 ↗
Route Intravenous “LTLD 50 mg/m2 will be administered intravenously over 30 minutes on day 1 of every 21-day cycle.” NCT04791228 ↗